Understand the science.
Follow the evidence.
From aging mechanisms to diagnostics, tissue repair and interventions. Keep the exact technology, study population and reported outcome in view.
Now in Longevity & Health
Recent source records organized by their stated dates. Open a source record to inspect or record a private claim review. Research, registrations, regulatory notices and institutional posts retain distinct evidence scopes.
Industry activity · Private operations
Sign in on EBIGRAPH to inspect current industry activity.
Initial coverage · 12 companies, 9 products and platforms, 3 registered studies and 2 separate reporting records. Company sources establish roles and stated programs; Registrations, reported findings and authorizations retain separate evidence scopes. Scheduled research discovery is separate from catalogue admission; inspect its private queue below.
Private scheduled discovery · Source leads
Browse recent source entries before selecting evidence for review. Research, animal studies, human trials, regulatory notices and authorized uses need distinct assessment. A registration or notice does not establish a treatment result or authorization.
Private database & source review
Load the live catalogue and review one exact source scope. Saved decisions retain their history; they do not approve efficacy or authorize publication.
Registry source intake & updates
Manually check the three registered study sources. Captures preserve the registry metadata; changes become private proposals. Acceptance creates a new catalogue snapshot and leaves earlier reviews attached to their earlier snapshot.
Company & research source intake
Check an existing company page or the NIA aging-biology research reference. Page captures retain their source and check date. Changed fingerprints await private review. Individual scientific findings need their own evidence records.
Longevity · research-paper intake
Initial research coverage across all four Longevity & Health branches. Bibliography, experimental models and authors’ reported findings are captured at abstract level. Full methods, clinical relevance and independent verification require separate assessment.
Clinical developments across Biotechnology
Moderna / Merck · Reported Phase 3 melanoma results →
Inspect the shared clinical-source record in Biotechnology. Cancer-study evidence does not establish an aging or longevity benefit. Longevity’s scheduled research leads and manually checked clinical sources keep their own evidence scopes.